StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) income statement

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07+0.00 (0.00%)

Close on Nov 18, 2026Market cap $773.79MP/E –Yield –

Monte Rosa Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-633.0%
Net margin
-560.8%
Return on equity, FY2025
-16.9%

Financial strength

Current ratio
10.58
Debt to equity
–
Debt to assets
–
Cash to current liabilities
151.0%

Valuation

P/E ratio
–
Price to sales
26.94
Price to book
1.59
Dividend yield
–

See a number that looks wrong?